

ERRATA

Tables 1 to 4 contained errors in the report "High-Dose Chemotherapy With Autologous Bone Marrow Transplantation for the Treatment of Metastatic Breast Cancer" by Eddy (J Clin Oncol 10:657-670, 1992).

They are reprinted here correctly in their entirety:

Table 1. Studies of HDC With ABMT for Metastatic Breast Cancer

Authors	Description	Treatment	No. of Patients*	Complete Response (%)	Partial Response (%)	Median Response Duration (months)	Median Survival (months)	% Survival† (years)					Treatment Deaths (%)
								1	2	3	4	5	
Dunphy et al ²	Stage IV; Rx±; M±; ER±, HU; I+; S/RI	C/VP-16/Cp	58	55	30	13.3	23	85	50	40		9	
Eder et al ³	Metastatic; unresectable; Rx±; M-; ER±; I-	C/Cp/BCNU	17	38	50	4-5	8	38	24			18	
Eder et al ⁴	Metastatic; refractory; Rx+; M±; ER±; I-	C/Tp/Cb	16	6	75	2							
Kennedy et al ⁵	Metastatic; Rx-; M±; ER±, HU; I+; RI	C/Tp	24	37	43	13‡	22‡	75‡	50‡	40‡		0	
Peters et al ⁶	Metastatic; Rx-; M-; ER-; I-	C/Cp/BCNU	22	54	19	9#	10.1	50	40	40	40	23	
Tannir et al ⁷	Metastatic; refractory; Rx+; M±; ER±; I+; NPD	AMSA	16	0	13	9							
Tannir et al ⁸	Metastatic; advanced; refractory; Rx+; M±; ER±; I±	Mito-C	15	0	6	<3						25	
Vincent et al ¹	Metastatic; advanced; Rx+; M±; ER±; I+; RCD	L-PAM	15	47	47	7§	12	66	22			20	
Wallerstein et al ⁹	Metastatic; relapsed; Rx+; M±; ER±; I+	Mitox/VP-16/Tp	32	23	39	4.5	9	44				13	
Williams et al ¹⁰	Stage IV; Rx-; M±; ER±, HU; I+; S/RI	C/Tp	22	55	32	6.2 ¶	not yet reached	60	50			18	

Abbreviations: Rx+, prior chemotherapy for metastatic disease; Rx-, no prior chemotherapy for metastatic disease; Rx±, mixed; Rx?, unknown, not stated; M+, postmenopausal; M-, premenopausal; M±, mixed; M?, unknown, not stated; ER+, estrogen receptor-positive; ER-, estrogen receptor-negative; ER±, mixed; ER?, unknown, not stated; HU, hormonally unresponsive; I+, induction given; I-, no induction; I±, mixed; I?, unknown, not stated; RI, responded to induction; S/RI, stable or responded; NPD, no progressive disease; RCD, response to conventional-dose chemotherapy; AMSA, amsacrine; BCNU, carmustine; C, cyclophosphamide; Cb, carboplatin; Cp, cisplatin; L-PAM, melphalan; Mito-C, mitomycin; Mitox, mitoxantrone; Tp, thiotepa; VP-16, etoposide.

*Number of patients receiving HDC with ABMT. Studies may include additional patients not receiving HDC.

†Survival rates were read from Kaplan-Meier curves and are approximate.

‡Includes all patients in the study: 24 women who responded to induction therapy and received HDC/ABMT and six women who did not.

§Time to treatment relapse.

||Only patients who received both induction and HDC/ABMT.

¶Time to treatment failure.

#For complete responders.

Table 2. Six Large Series of Patients With Metastatic Breast Cancer Not Treated With HDC

Authors	Description	Stage of Cancer	No. of Patients	Complete Response	Partial Response	Median Survival (months)	% Survival* (years)					
							1	2	3	4	5	
Clark et al ⁷³	Large series; retrospective review	Recurrent	1,015			23						
Falkson et al ⁷⁴	Large series, Rx-; 36-55 years old	Recurrent	646			24	75	50	35	25		
Mick et al ⁷⁵	CALGB protocols; Rx-; all < 55 years old	IV	432			18	70	42	26	18		
Sondik ⁷⁶	National data base; newly diagnosed cases	IV	3,407			24	70	36	27	21		
Swenerton et al ⁷⁷	Large series; retrospective review	Metastatic	619	16%	48%	21	80	43	27			
Vincent et al ¹	Conventional Rx	Advanced; metastatic	113			12	66	22				

Abbreviations: Rx-, no prior chemotherapy for metastatic disease; CALGB, Cancer and Leukemia Group B.

*Survival rates were read from Kaplan-Meier curves and are approximate.

Table 3. 39 Randomized Controlled Trials of Conventional-Dose Chemotherapy for Metastatic Breast Cancer

Authors	Description	Treatment Group	No. of Patients	Complete Response (%)	Partial Response (%)	Median Response Duration (months)	Median Survival (months)	% Survival* (years)					Treatment Deaths (%)
								1	2	3	4	5	
Australian and New Zealand Breast Cancer Trial Group ⁷⁸	Recurrent or metastatic; Rx-; M+; ER±; I-	TAC	113	7	44			75	44	28	17	9	
		AC	113	9	36			72	37	21	12	11	
		T	113	7	15			73	48	27	18	12	
Bennett et al ⁷⁹	Metastatic; Rx-; M±; ER±; I-	CNF	167	4	25	5.6	12.4						
		CAF	164	4	33	8.4	12.7						
Bezwoda et al ⁸⁰	Recurrent or metastatic; Rx-; M±; ER+; I-	T	24	21	42	12.7	17.1						
		TCMF	26	12	54	7.4	17.7						
Bull et al ⁸¹	Progressive metastatic; Rx-; M±; E±; I-	CMF	40	8	55		17.0	65	20				
		CAF	38	18	63		27.2	76	55				
Canellos et al ⁸²	Metastatic; Rx-; M±; ER±; I-	CMF	93	15	38	6.0	12.0	45					
		L-PAM	91	5	14	3.0	9.0	29					
Cavalli et al ⁸⁴	Measurable advanced; Rx-; M-; ER±; I-	conc Rx†	55	0	45			90	53	38	22		
		seq Rx†	54	0	43			78	38	22			
		conc Rx†	152	0	39			72	50	33	20		
Chlebowski et al ⁸⁵	Metastatic; Rx-; M±; ER±; I-	seq Rx†	145	0	33			78	59	41	28		
		comb Rx†	61					14.8					
Coates et al ⁸⁶	Recurrent or metastatic; advanced; Rx-; M±; ER±; I-	seq Rx†	60					11.4					
		cont AC	79	6	43			36	13	1	0	0	
Cocconi et al ⁸⁷	Advanced; progressive metastatic; Rx-; M+; ER±; I+; S/RI	inter AC	73	1	32			28	10	2	0	3	
		cont CMFP	75	7	41			32	9	3	0	1	
		inter CMFP	78	4	28			30	8	3	0	6	
		CMF† + AVi	46	2§	8§	16	34.1	91	72			18	
Cummings et al ⁸⁸	Metastatic or recurrent; Rx-; M±; ER±; I-	CMF†	49	2§	8§	16	34.1	91	72			18	
		CAF	79	18	37	11.0	18.6	68	38	18			
Elomaa et al ⁹⁰	Metastatic; Rx+; M±; ER±; I-	CMFP	76	7	46	6.3	15.8	60	40	24			
		CAF	79	18	37	11.0	18.6	68	38	18			
Falkson et al ⁹¹	Metastatic; Rx-; M-; ER±; I-	A	22	0	23	6.7	8.0						
		AMPA	21	0	14	7.0	8.0						
Falkson et al ⁹²	Metastatic or recurrent; Rx-; M-; ER±; I-	ViPCMF	54	30	41		26.0	78	57	30			
		C	56	36	27		23.0	80	48	30			
		OB + ViPCMF	38	19	31		30.0	82	63	38			
French Epirubicin Study Group ⁹³	Advanced; recurrent or metastatic; Rx-; M±; ER±; I-	CAF	38	24	53		70	60	45	18			
		O + CAF	43	35	49		88	65	54			3	
French Epirubicin Study Group ⁹⁴	Advanced; progressive; metastatic; Rx+; M±; ER±; I-	FEC	117	12	38	10.4	14.8	55	22	10			
		FAC	113	8	44	11.7	17.4	69	31	23	15		
Gasparini et al ⁹⁶	Recurrent or metastatic; Rx-; M±; ER±; I-	FEC 50	129	6	36	12.4		71	38	25			
		FEC 75	130	15	28	13.0		73	46	25			
		E	132	4	24	10.5		63	38	19			
Gunderson et al ⁹⁷	Advanced; metastatic; Rx±; M±; ER±; I-	E	22	0	36		12.0	50					
		A	21	5	33		11.0	50					
Habeshaw et al ⁹⁸	Advanced; metastatic; Rx±; M±; ER±; I-	A	81	2	33		14.0	57	22				
		E	68	3	19		14.0	57	17				
Henderson et al ⁹⁹	Advanced; metastatic; Rx±; M±; ER±; I-	LDEP	104	4	19		10.6						1
		HDEP	105	10	31		10.2						
Henderson et al ⁹⁹	Metastatic; Rx+; M±; ER±; I-	Mitox	165	2.4		5.0	9.0	37.5	23				
		A	160	3.1		4.1	8.8	35	12.5				

Continued on following page

Table 3. 39 Randomized Controlled Trials of Conventional-Dose Chemotherapy for Metastatic Breast Cancer (Cont'd)

Authors	Description	Treatment Group	No. of Patients	Complete Response (%)	Partial Response (%)	Median Response Duration (months)	Median Survival (months)	% Survival* (years)					Treatment Deaths (%)
								1	2	3	4	5	
Hortobagyi et al ¹⁰⁰	Metastatic; Rx-; M±; ER±; I-	SD FAC	27	22	56	10.0	20.0	70	44	36	25	25	
		HD FAC	32	25	53	11.0	20.0	66	40	22	16	9	
Hortobagyi et al ¹⁰¹	Metastatic; progressive, refractory; Rx+; M±; ER±; I-	A	21	5	24	5.0	10.0						
		E infusion	27	0	26	4.0	9.0						
Ingle et al ¹⁰³	Metastatic; progressive refractory; Rx+; M±; ER±; I-	E bolus	23	0	13	6.0	7.0						
		A	95	0	20	5.7	8.4	35	8	0			1
Ingle et al ¹⁰⁴	Metastatic; Rx±; M+; ER±; I-	A/Vi/Mito-C	90	3	29	5.3	9.2	37	14	9			1
		T	119	12	30	15.6	30.1	78	60	40	34	22	
Italian Multicentre Breast Study With Epirubicin ¹⁰⁵	Advanced; failed; Rx±; M±; ER±; I-	TF	119	23	31	15.6	32.2	80	62	45	29	20	
		FEC	222					72	42				
Lopez et al ¹⁰⁶	Recurrent or metastatic; Rx±; M±; ER±; I-	FAC	221					80	42	20			
		A	37	11	35	6.0	20.0	78	44				
Marschke et al ¹⁰⁷	Metastatic; Rx-; M±; ER±; I-	I	34	6	15	5.0	14.0	59	31				
		CFP	166	4	27	7.1	15.2	56	35	12	8	7	
Muss et al ¹⁰⁸	Advanced; Rx+; M±; ER±; I±	CMFP	170	9	29	8.5	14.9	62	24	12	10	7	
		CAViFP	52	10	46	16.2		65	38	15			
Nemoto et al ¹¹⁰	Metastatic; Rx-; M+; ER±; I-	CAViFP + MER	50	12	42	14.0		73	44	19			
		CA/MF	53	8	36	12.1		65	36	20			
		CA/MF + MER	42	5	38	15.5		62	45	10			
		CFP	18	0	17			53	35	8	0		
Rosner et al ¹¹¹	Metastatic; progressive measurable; Rx-; M±; ER±; I-	CFP-CA	20	0	60			70	26	20	13		
		CAF	46	6.5	15			65	24	5	3	0	
		CA	42	2	38			68	31	8	3	0	
		CFP-CFPMVi-CA	46				16.6	60	34	21	21		4
Rossof et al ¹¹²	Metastatic or recurrent; progressive measurable; Rx-; M-; ER±; I-	CFPMVi-CA-CFP	48				17.6	58	31	20	5		
		CA-CFP-CFPMVi	47				12.3	54	22	10	0		
Rubens et al ¹¹³	Advanced; Rx-; M±; ER±; I-	CMF	20	25	45	17.5††	41.3	96	82	70	43	43	
		OB	14	21	14	6.1††	40.4	79	62	60	43	24	
Smalley et al ¹¹⁴	Metastatic or recurrent; Rx-; M±; ER±; I-	M-; ER±; I-											
		C	49	4	51	5.5		28	11				2
Spittle et al ¹¹⁵	Progressive advanced; metastatic; Rx±; M±; ER±; I-	CMFV	50	2	60	7.0		37	8	4			2
		cont MFViCP	35	11	34	6.5	11.1	45	9				8.5
Tannock et al ¹¹⁶	Metastatic; Rx-; M±; ER±; I-	inter MFViCP	33	12	15	7.8	11.1	38	9				9
		seq MFViCP**	34	6	15	3.7	5.5	30	11				6
Taylor et al ¹¹⁷	Recurrent or metastatic; stage IV; Rx-; M+ ††; ER±; I-	AViFM	131		63§§			56	28	21	16		
		ViAM alt FVdC	131		64§§			62	25	15	10		
Tormey et al ¹¹⁸	Recurrent or metastatic; Rx-; M±; ER±; I+	LD CMF	67				12.8	50	10	5			
		CMF	79	15	42	4.5	14.5	65	24				
Tranum et al ^{119¶¶}	Metastatic; Rx-; M±; ER±; I-	HD CMF	66				15.6	70	24	10	2		
		T	95				10.4	23.3	75	50	36	25	
Tranum et al ^{119¶¶}	Metastatic; Rx-; M±; ER±; I-	CMF	86				7.9	20.9	65	44	24	18	
		AVi	166	12	44	7.7	13.7	57	24	13	0		
		CMF	79	15	42	4.5	14.5	65	24				
Tranum et al ^{119¶¶}	Metastatic; Rx-; M±; ER±; I-	CMFP	86	16	47	8.4	16.4	65	36	26	17		
		FA	105	10	32	5.1	14.1						
		FAC	103	14	29	~7.8	14.1						3.5
Tranum et al ^{119¶¶}	Metastatic; Rx-; M±; ER±; I-	FACM	105	11	38	~7.8	15.0						

Continued on following page

Table 3. 39 Randomized Controlled Trials of Conventional-Dose Chemotherapy for Metastatic Breast Cancer (Cont'd)

Authors	Description	Treatment Group	No. of Patients	Complete Response (%)	Partial Response (%)	Median Response Duration (months)	Median Survival (months)	% Survival* (years)					Treatment Deaths (%)
								1	2	3	4	5	
Tranum et al ¹²⁰	Advanced; Rx-; M±; ER±; I-	AC	140	10	31	6.7	20.5	63	41	18			2.5
		FAC	160	10	38	12.0	19.4	70	41	0			
		A + CViMFP	148	11	35	8.5	17.5	65	35	23			
Vaughn et al ¹²¹	Advanced; Rx+; M±; ER±; I-	A	59	5	19		8.5	35	12	8	5	2	1
		AVP-16	56	5	18		9.8	42	20	8	8	0	

Abbreviations: A, doxorubicin; alt, alternating with; AG, aminoglutethimide; ch, chlorambucil; comb, combination; conc, concurrent; cont, continuous; conv, conventional; E, epirubicin; F, fluorouracil; FLU, fluoxymesterone; HD, high-dose; I, idarubicin; inf, infusion; inter, intermittent; LD, low-dose; L-PAM, melphalan; M, methotrexate; MA, megestrol acetate; MER, bacillus Calmette-Guérin; MPA, medroxyprogesterone acetate; N, Novantrone (mitoxantrone; Lederle Laboratories, Wayne, NJ); O, oophorectomy; OB, observation; P, prednisone; SD, standard-dose; seq, sequential; T, tamoxifen; V, vinblastine; Vd, vindesine; Vi, vincristine.

*Survival rates were read from Kaplan-Meier curves and are approximate.

†Cytotoxic drugs.

‡Cyclophosphamide, methotrexate, prednisone, triiodothyronine (liothyronine).

§Response rates are for those who converted after randomization and do not include any response achieved during induction.

||Includes all patients who responded, both during induction and after randomization.

¶Regimen consisted of two alternating drugs from the CMF combination.

#Cyclophosphamide used as intensification.

**Each drug in sequence until relapse.

††All older than 65 years.

‡‡Time to treatment failure.

§§All responses considered partial.

|||In responders.

¶¶Prospective; controlled; "randomization" not mentioned.

Table 4. Balance Sheet for HDC and ABMT for Treatment of Stage IV Breast Cancer

Health Outcomes	Best Guesses of Probability or Magnitude of Outcome		
	Regular-Dose Chemotherapy	HDC With ABMT	Difference
Benefits			
Relief of Symptoms	?	?	?
Complete response (IO)	10.1%?	36%?	+26%?
Overall response (IO)	41%?	70%?	+29%?
Median response duration	8.8 mos?	8.3 mos?	-0.5 mo?
Median survival	16.2 mos?	16 mos?	-0.2 mo?
2-year survival	39%?	43%?	+4%?
Harms			
Death due to bone marrow toxicity	1%?	13.5%?	+12.5%?
Extramedullary toxicity	0%?	30%?	+30%?
Secondary effects of bone marrow suppression; infection	3%?	75%?	+72%?
Side effects of chemotherapy			
Alopecia	75%	100%?	+25%?
Nausea	50%	100%?	+50%?
Vomiting	40%	100%?	+60%?
Stomatitis	20%?	75%?	+55%?
Diarrhea	10%?	75%?	+65%?

NOTE. Estimates are rounded and question marks are added to emphasize that there is a wide range of uncertainty around every estimate.